glp 1 agonist and alcohol use disorder GLP-1 Agonists for Disorder: UK Evidence Guidance GLP-1 Receptor Agonists as Treatments

Back Thim, L, Moody, AJ (May 1981) 'The primary structure of porcine glicentin (proglucagon)', Regulatory Peptides , 2/2

Multiple generics of liraglutide (Victoza) are available for the treatment of T2DM

analyzed commercial claims data (see Figure 2) and found that persistent GLP-1 users had $14K-$15K (about 14%) lower average annual total cost of care in the first one to two years of use compared with chronically obese patients who never tried GLP-1s

95% CI 0.09, 0.1), GLP-1 RAs/metformin (WMD: 0.31

Similar recommendations were made by the European Medicines Agency (EMA) that required including major adverse cardiovascular events (MACE) as a primary endpoint ( These regulatory requirements led to the discovery of cardiovascular benefits in GLP-1R agonists, demonstrating the importance of due diligence and proactive safety monitoring

Wing RR, Bolin P, Bracanti FL et al